The short answer
GLOW is a co-lyophilised research blend of three peptides in one vial: GHK-Cu at 402.92 Da, BPC-157 at 1419.5 Da and TB-500 (full-length thymosin beta-4) at 4,963 Da, totalling 70mg. The per-component split is not stated, which is the defining limitation of the format.
Key facts
- Components
- Three
- GHK-Cu
- 402.92 Da, CID 71587328
- BPC-157
- 1419.5 Da, CID 9941957
- TB-500 (thymosin beta-4)
- 4,963 Da
- Total mass
- 70 mg
- Per-component split
- Not stated
- Form
- Co-lyophilised, single vial
- Authorisation
- None (components are unlicensed)
What co-lyophilised means
The GLOW peptide blend is three peptides combined in solution and freeze-dried together: one cake in one vial rather than three separate products. Reconstituting it puts all three into solution simultaneously, in whatever ratio was set at manufacture.
The three components
GHK-Cu is a copper-complexed tripeptide at 402.92 Da, associated with collagen and matrix remodelling research. BPC-157 is a fifteen-residue peptide at 1419.5 Da with a large preclinical repair literature and a recruiting Phase 2 trial. TB-500 here is full-length thymosin beta-4, 43 residues at 4,963 Da. Each has its own category on this site. The KLOW stack combines these same three components with KPV at 80mg total.
Research material referenced
GLOW 70mg, third-party HPLC tested
The figure that is missing
70mg is a total. How that divides between three components is not stated, and every calculation anyone would want to perform requires knowing. This is not a criticism of one product. It is inherent to the blend format, and stating it clearly is more useful than working around it.
Why the components were chosen together
All three appear in connective tissue and matrix research literatures. GHK-Cu in collagen and remodelling work, BPC-157 in repair models, TB-500 in cell migration studies. The rationale is overlap of research area rather than any demonstrated interaction between them.
What has not been demonstrated
That the three do anything together that they do not do separately. There is no published work on this specific combination. The literature exists for each component individually. A blend is a convenience of packaging, not a studied entity, and no synergy claim can be supported.
Regulatory position
None of the three components holds a marketing authorisation from the MHRA, EMA or FDA, and neither does the blend. It is supplied for laboratory research only, with no claim about skin, ageing or any condition in any person.
Frequently asked questions
What is in GLOW?
GHK-Cu at 402.92 Da, BPC-157 at 1419.5 Da and TB-500 (full-length thymosin beta-4) at 4,963 Da, co-lyophilised together, totalling 70mg.
How much of each component is there?
The split is not stated. That is the defining limitation of a blend format, and it affects every calculation.
Is there research on the combination?
No. The literature exists for each component separately. No published work addresses this specific blend.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubChemPubChem · GHK-Cu copper complex (CID 71587328)pubchem.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- PubMedPickart L & Margolina A, GHK Peptide as a Natural Modulator of Multiple Cellular Pathways. Biomed Res Int 2015 (PMID 26236730)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Stable gastric pentadecapeptide BPC 157. Curr Pharm Des 2011 (PMID 21548867)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLOW (Blend) articles
- The Copper Question in This BlendCopper is redox-active and catalyses thiol and thioether oxidation. None of the co-blended peptides contains cysteine or methionine - which is why this works.
- A Blend Fixes the Ratio and Keeps the ComplexityA co-lyophilised blend has a multi-agonist's fixed ratio without a single molecule's single pharmacokinetic profile. What that actually costs.
- One Volume, Three PeptidesThree peptides with different sizes and solubilities dissolve at different rates in one vial. What that means for technique and for patience.
- Storing a Blend: The Weakest Component GovernsThree peptides in one vial cannot be stored under three different conditions. The most demanding component sets the requirement for all of them.